Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| GitLab | Celestica | Moderna | |
|---|---|---|---|
| Moat rating | narrow The FY2026 10-K (year ended 2026-01-31) shows real expansion inside the installed base: 118% Dollar-Based Net Retention, Base Customers up to 10,682 from 9,893, customers above $100,000 of ARR up to 1,456 from 1,229, and $1.0 million ARR customers "to 155 from 123, an increase of 26%". But the filing concedes "limited barriers to entry" and names "Microsoft Corporation, which owns GitHub" as principal competitor. Retention decelerates (130% FY2024, 123% FY2025, 118% FY2026), and since DBNR is reported "on a threshold basis of 130%," the FY2024 figure is a cap and the slide is steeper than it looks. Narrow, not wide: expansion must be re-won against a bundled hyperscaler. | narrow The FY2025 10-K shows a real but bounded edge. On the durable side, Celestica is increasingly engaged as an ODM: its HPS business co-designs (JDM) or fully designs the platforms it builds, it states 'We have hardware and software patents that are integral to our HPS business' and that 'our increased R&D activities have resulted in the growth of our dependence on our patent portfolio', and HPS reached 41% of total revenue in 2025 (from 21% in 2023) at a margin profile the filing says is higher than traditional EMS work. On the limiting side, the same filing concedes 'Some of our competitors have greater scale and provide a broader range of services than we provide', the master supply agreements 'do not typically guarantee a particular level of business or fixed pricing', work is won 'on a program-by-program basis', and the top 10 customers were 79% of 2025 revenue with three customers individually at 32%, 14% and 12%. An advantage that must be re-won each program against greater-scale rivals, for a handful of buyers who can in-source, is narrow rather than wide. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | switching costs Stickiness comes from platform embedding, not IP. The 10-K rests differentiation on "our single platform with a unified data model," on "Consolidation of multiple tools into a single platform," and on deployment inside the customer's own perimeter for regulated buyers. Replacement means re-integrating a toolchain and re-certifying compliance. IP is the wrong label: only "16 issued patents and 25 pending patent applications," plus open-source licenses granting "broad permissions to use, copy, modify, and redistribute." The no-lock-in claim is the filing's own characterisation, footnoted to a Forrester study "commissioned by GitLab." | switching costs Cost scale is explicitly not the source: the 10-K states competitors have greater scale and a broader service range. What does bind a customer is the design-in. Within HPS, Celestica 'design[s] and manufacture[s] products, either as customized solutions, white box solutions or under Joint Design and Manufacturing (JDM) engagements', holds 'hardware and software patents that are integral to our HPS business', and delivers 'complete platform solutions... integration and orchestration of various technologies into rack-scale designs'. The filing adds that 'a majority of these supply agreements also require the customer to purchase unused inventory that we have purchased to fulfill that customer's forecasted manufacturing demand', a contractual cost of walking away mid-program. Moving a qualified, jointly designed rack-scale platform to another ODM means requalifying a design Celestica partly owns, which is friction the commodity assembly work does not carry. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | fast follower The 10-K positions GitLab against a leader rather than as one: "Our principal competitor is Microsoft Corporation, which owns GitHub." Competition reads from the challenger side, differentiating "from GitHub through flexible deployment options that work within enterprise security and compliance requirements, LLM neutrality with self-hosted gateway support" and an open core model. On AI it follows: Duo Agent Platform went "Generally available in January 2026," the last month of the fiscal year. What keeps it a follower rather than behind is cadence, "a new version of our software every month for 172 months in a row," plus a regulated-deployment franchise a SaaS-first rival does not cover. | at parity The 10-K claims no share leadership. It states plainly that 'Some of our competitors have greater scale and provide a broader range of services than we provide', and lists Hon Hai, Flex, Jabil, Sanmina, Benchmark and Plexus in EMS plus Quanta, Wiwynn and Accton in ODM. Its stated competitive advantage is execution quality, not position: 'our track record in advanced manufacturing capabilities, design and engineering, quality, delivery, managing complexity and responsiveness'. It is also winning: CCS revenue grew 42% to $9.19 billion and total revenue reached $12.39 billion in FY2025. Competing on comparable terms with a field it neither leads nor trails is parity. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | moderate FY2026 gross margin was 87% against 89%, with cost of revenue up $35.6 million "primarily due to an increase of $18.4 million in third party hosting costs for SaaS and cloud usage," and management expects SaaS and Duo mix to bring costs that "may adversely impact our gross margins." Strain is explicit: GitLab "may be required to reduce our prices," competitors "may offer their products and services at a lower price or for free," and it "implemented user limits on our free SaaS product." Power retained: Premium lists at $29 per user/month billed annually, and seats bundle $12 and $24 of GitLab Credits. But "A majority of our subscriptions are on a one-year period." | weak The filing describes price as contested by contract, not set by Celestica: master supply agreements 'do not typically guarantee a particular level of business or fixed pricing', 'Some of these agreements require us to provide specific price reductions to our customers over the term of the contracts', and the Item 1A risk factor 'We operate in an industry comprised of numerous competitors and aggressive pricing dynamics' says competitors may be 'willing to, or able to make sales or provide services at lower margins than we do'. The site's fundamentals show gross margin at 12.06% in FY2025, up from 8.96% in FY2022, 9.47% in FY2023 and 10.72% in FY2024 — improving, but still low double digits, and the filing attributes the higher margin to mix (HPS is 'higher margin profile than our traditional EMS businesses' and went from 21% to 41% of revenue over the same span) rather than to raising prices. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | GitLab sells a single-platform DevSecOps toolchain defended by workflow lock-in rather than intellectual property: a unified data model plus deployment flexibility, including single-tenant "Dedicated for Government with FedRAMP compliance," makes it hard to remove where data residency is contractual. The installed base expands: 118% Dollar-Based Net Retention, 10,682 Base Customers, 1,456 above $100,000 of ARR, 155 above $1.0 million (up 26%), over 70% of ARR from public sector and enterprise. The filing supplies the counterweight: "limited barriers to entry," Microsoft/GitHub as principal competitor, 16 issued patents. Retention (130 to 123 to 118, the 130 a cap), gross margin (89% to 87%) and a January 2026 AI launch point to compression at the commodity end. No source measures market share, so every share band is "unknown". | Celestica is a contract design and manufacturing company that has been pulled up the value chain by the AI data-center build-out. Its CCS segment, which builds networking switches, optical systems, data center racks, servers and storage for hyperscalers and other cloud and AI service providers, grew 42% to $9.19 billion in 2025, and Communications alone went from 33% of revenue in 2023 to 57% in 2025. The part of that business with a defensible position is HPS, where Celestica is the designer rather than the assembler: HPS revenue rose 81% in 2025 to 41% of the total, carries a higher margin than traditional EMS work, and rests on a patent portfolio the filing calls integral to the business. That design-in position is what separates it from pure build-to-print capacity. What caps the moat is the customer side of the ledger. The 10-K describes an industry where 'aggressive pricing is a common business dynamic', where master supply agreements guarantee neither volume nor price and some of them 'require us to provide specific price reductions to our customers over the term of the contracts', and where the company bids program by program against Hon Hai, Flex, Jabil, Sanmina, Benchmark and Plexus on the EMS side and Quanta, Wiwynn and Accton on the ODM side, plus Arista and Cisco where a customer might buy an off-the-shelf switch instead. Revenue concentration has tightened as the AI mix grew, from 64% of revenue in the top 10 customers in 2023 to 79% in 2025, with a single customer at 32%. The company also notes its HPS offerings can compete with a customer's own hardware, which may 'negatively impact our relationship with, or result in a loss of business from, such customers'. So the profile is a genuine but program-scoped advantage, held by a company whose fortunes turn on a few buyers' capital plans. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | GitLab sits at the software-tooling layer, not compute or models. It consumes third-party LLM capacity — marketing "LLM neutrality and support for self-hosted AI gateways, including air-gapped environments" — so it captures no model-layer economics and bears inference as COGS, visible in the $18.4 million rise in hosting costs. Its distinctive position is the regulated perimeter. | Celestica sits between component suppliers and the hyperscale buyer, and owns the design only in part of that span. It 'procure[s] substantially all of our materials and components on behalf of our customers pursuant to individual purchase orders that are generally short-term in nature', then designs, assembles, integrates at rack scale and tests the switches, optical systems, servers, storage and data-center racks that cloud, AI and enterprise customers deploy. In ATS it is a pure EMS contractor that does 'not generally collaborate with ATS customers on the design of the solutions we manufacture'; in HPS it is the designer of record or a joint designer. The economics follow that split: the segment where it holds design IP is the one with the higher margin profile. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |